One-Step Aqueous Enteric Coating Systems: Scale-Up Evaluation

Size: px
Start display at page:

Download "One-Step Aqueous Enteric Coating Systems: Scale-Up Evaluation"

Transcription

1 One-Step Aqueous Enteric Coating Systems: Scale-Up Evaluation Charles R. Cunningham* and Kurt A. Fegely Two aqueous enteric coating systems, poly(vinyl acetate) phthalate based Sureteric and acrylicbased Acryl-Eze, were evaluated for coating performance on acetylsalicylic acid 81-mg tablets. Both systems provided acceptable acid resistance at coating weight gains as low as 6%, which were achieved in as little as 1.9 h for a 130-kg batch size. Tablets coated with each system out-performed the USP requirements for dissolution and free salicylic acid levels initially and after three months storage at 40 C and 75% RH. PHOTODISC, INC. Aqueous enteric coating systems have been widely used for many years and offer substantial advantages over solvent systems, particularly with regard to environmental and toxicological concerns. Although these formulated aqueous enteric coating systems were an advancement from traditional solvent systems, they required the separate addition of plasticizers, detackifiers, pigments, and other process aids (1). Through the years, little reduction has taken place in the complexity of these systems (2). Selection of the optimal additives for each formulation adds time to the development of individual formulations (3 5). Multiple, time-consuming steps also are required in the preparation of these aqueous enteric coating dispersions (6). In addition, many of these systems are provided as liquid dispersions, which can be problematic when handling, transporting, and controlling storage conditions. Two fully formulated, aqueous enteric coating systems now are commercially available. The systems are based on two different acid-insoluble polymers. The Sureteric system is based on poly(vinyl acetate) phthalate (PVAP), and the Acryl-Eze system is based on methacrylic acid copolymer type C (Eudragit L100-55, Röhm GmbH, Darmstadt, Germany). Both systems are dry dispersible powders that do not require the use of any additional plasticizers, detackifiers, or neutralization agents. This study evaluated both systems for ease of use and acid resistance characteristics in the production-scale film coating of acetylsalicylic acid (ASA) 81-mg tablets. Charles R. Cunningham is a global technical manager in global technical support, and Kurt A. Fegely is group leader in new product development, both at Colorcon, 415 Moyer Blvd., West Point, PA 19486, tel , fax *To whom all correspondence should be addressed. Materials and equipment The tablet formulation contained ASA 40-mesh crystals (aspirin 1040, Rhodia, Cranbury, NJ), partially pregelatinized corn starch (Starch 1500, Colorcon, West Point, PA), microcrystalline cellulose (Emcocel 50M, Penwest, Patterson, NY), and stearic acid NF (purified vegetable-grade powder, Oleotec Ltd., London, UK). The tablet ingredients were dry blended in a 40-ft 3 twin-shell blender (Patterson-Kelley Co., East Stroudsburg, PA). Tablets were compressed on a 30-station rotary press (Type B4, Manesty, Liverpool, UK) using 7-mm standard concave type B tooling (Natoli Engineering Co., St. Charles, MO). Tablet hardness and weight variation were measured using a Multichek tester (Erweka, Milford, CT). 36 Pharmaceutical Technology NOVEMBER

2 Table I: Composition of the coating dispersions. Component % Weight (kg) % Weight (kg) Coating solids Deionized water Total * * 65.0 g of antifoam emulsion was added to the water before the acrylic powder. Table II: Uncoated ASA 81-mg tablet properties. Test Average Standard Deviation Weight (mg) n Breaking force (kp) n Friability (%) 20 tablets 0.12 Disintegration time in water (min) n Table III: Mixing time comparison (in minutes). Mixing Step Antifoam addition 0.5 Enteric powder addition Mixing before coating Filtration through screen Total dispersion preparation time Table IV: Coating process conditions. Process Parameter PVAP-Based Acrylic-Based Average inlet temperature ( C) Average exhaust temperature ( C) Average tablet-bed temperature ( C) Average spray rate (g/min) Atomizing air pressure (bar) Fan air pressure (bar) Pan speed (rpm) Airflow (m 3 /h) Total spray time (min) The coating materials used were the PVAP-based white aqueous enteric coating system (Sureteric) and the methacrylic acid copolymer (acrylic) based pigmented aqueous enteric film coating system (Acryl-Eze), both manufactured by Colorcon. An antifoaming agent (30% simethicone emulsion USP, Dow Chemical Co., Midland, MI) was used in the preparation of the acrylic-based system. The PVAP-based dispersion was prepared using a model RW 28 DX mixer (IKA Labortechnik, Staufen, Germany). A model AX3 mixer (Silverson Machines Ltd., Chesham Bucks, UK) was used to prepare the acrylic-based dispersion. Early mixing guidelines for the acrylic-based product recommended the use of a high-shear mixer such as the AX3. Subsequent technical literature indicates that either high- or low-shear mixing can be used for preparing the coating dispersion (7). A side-vented 48-in. coating pan (Accelacota 150, Manesty, Liverpool, UK) was used to apply the coatings. Acid uptake testing was performed using a disintegration-testing apparatus (model ZT54, Erweka, Milford, CT). An automated dissolution test station (VK- 7010, apparatus I, VanKel, Cary, NC) with a UV spectrophotometer (Varian, Palo Alto, CA) was used for drug-release testing. An HPLC system (Alliance 2690, Waters Corp., Milford, MA) was used for free salicylic acid determinations. The packaging materials used for stability testing of the coated tablets were 85-cm 3 foil sealable HDPE bottles (Drug Plastics and Glass Co., Boyertown, PA) and desiccant packs (3964, Süd-Chemie Performance Packaging, Belen, NM). Methods Blending and tablet preparation. ASA, microcrystalline cellulose, partially pregelatinized starch, and stearic acid were blended for 20 min in the twin-shell blender. The batch size was 560 kg. The blend was compressed to a target tablet weight of 170 mg, and the compaction force was adjusted to produce tablets with a breaking force of 8 kp and 0.25% friability. Press speed was 42 rpm for a production rate of 75,600 tablets/h. Preparation of the coating dispersions. Coating dispersions were prepared by adding the dry aqueous enteric coating formulations directly into a mixing tank filled with deionized water (ambient ~20 C). Mixer speed was controlled to produce and maintain a deep center liquid vortex into which the powder was added. For the acrylic-based system, antifoam was added to the water just before the addition of the powder to reduce foam generated during the initial high-speed mixing. Immediately after the addition of the powder to the water, the mixer speeds were reduced to maintain gentle stirring. This was done for both coating polymer systems. The coating systems were dispersed at the solids concentration recommended by the manufacturer. A sufficient amount of each coating dispersion was prepared to apply a theoretical 10% weight gain of coating to the tablets (see Table I). Each of the dispersions was screened through a 250- m sieve before coating. Spray coating. Tablet coating was carried out in the 48-in. sidevented pan equipped with four spray guns. The coating dispersions were delivered to the spray guns through individual tubes fed from a peristaltic pump. The pan load of ASA 81-mg tablets was 130 kg. The coating process controls were set using the parameters recommended by the manufacturer for the enteric coating systems. Samples of tablets for performance testing were removed from the coating pan at increments from 5 10% theoretical coating weight gain. Process data were recorded throughout the trials. Acid uptake testing. A variation of the gastro-resistant tablet disintegration method (European Pharmacopoeia Third Edition 2001) was used. In this revised method, six coated tablets were weighed individually and placed in the disintegration basket tubes. We immersed the disintegration basket in 900 ml of 38 Pharmaceutical Technology NOVEMBER

3 0.1 N hydrochloric acid and operated the apparatus for 2 h. The individual tablets that were still intact then were dried with a towel and reweighed. The percent of weight increase was reported as % acid uptake. Tablets that fully disintegrated during the testing were counted as having 100% acid uptake. This method has been reported to provide an accurate measure of acid resistance of the coating, and acid uptake values 5% suggest that the tablets would readily pass the acid phase of the delayed-release dissolution testing (8). Dissolution and free salicylic acid testing. The dissolution and free salicylic acid tests for the coated tablets were performed according to the USP 24 monograph for delayed-release ASA tablets. Packaging and stability. Two sets of coated tablets from each trial were packaged in high-density polyethylene (HDPE) bottles (120 tablets/bottle). One set was packaged with desiccant and the other without. All bottles were induction (foil) sealed and placed in a chamber for three months at 40 C and 75% RH. Results and discussion Uncoated aspirin tablets. Tablets used in a functional coating process must be sufficiently robust to withstand mechanical stresses and to exhibit very low potential for erosion and edge chipping. Any defects in the tablet core may result in a localized weakness of the functional film. A subcoating process may be used to strengthen friable cores before the application of the Table V: Dissolution results. % Released in t 80% in % Released in t 80% in Theoretical 0.1 N HCL Phosphate Buffer 0.1 N HCL Phosphate Buffer Weight Gain (%) after 2 h (ph 6.8) after 2 h (ph 6.8) min min min min min min min min min min Table VI: Dissolution stability. % Released in t 80% in % Released in t 80% in Theoretical 0.1 N HCL Phosphate Buffer 0.1 N HCL Phosphate Buffer Weight Gain (%) after 2 h (ph 6.8) after 2 h (ph 6.8) Packaged without Desiccant 6 25 not tested min min min min min min min min min Packaged with Desiccant min min min min min min min min min min functional coat but is not desirable in terms of process time and complexity. Subcoats also may be necessary to prevent interaction between the drug substance and the coating formulation ingredients. Interactions between the ASA and either of the enteric coating systems in this study were not expected. In this study, the ASA 81-mg tablets were sufficiently robust to avoid the use of a subcoat step (See Table II). Dispersion mixing time. Because both polymer systems are fully formulated, the mixing process consisted of a simple addition of the powder formulations to the water. The total preparation time was very short for both systems (see Table III). Filtration of the material before coating was performed to ensure that no undispersed particles of polymer remained that could result in gun blockages. Coating process. The coating process for each trial was conducted using the recommended coating conditions for each coating system (9,10). The gun-to-bed distance was 24 cm, and the distance between guns was 18 cm. The spray applications were continuous from start to finish, and spray rates were held constant throughout the coating trials. The coating data are listed in Table IV. The acrylic-based system required a lower tablet-bed temperature than did the PVAP system, and the spray rate for the acrylic-based system was slightly lower. The total coating time for the acrylic-based system was shorter because of the higher solids concentration of the dispersion. The tablets were not dried further after the application of the coatings other than during a cooldown period in the pan before unloading. Coating process efficiency for both systems was 90% on the basis of the calculation of tablet-weight difference before and after coating. The coating process for both systems was free of any problems. The coated tablets had no obvious defects or signs of sticking or tackiness (see Figure 1). Acid resistance testing. Samples of the 40 Pharmaceutical Technology NOVEMBER (a) (b) Figure 1: Photographs of coated tablets (theoretical 10% weight gain). Tablets are coated with (a) the acrylic-based system and (b) the PVAPbased system.

4 % Acid uptake % Enteric coating theoretical weight gain Figure 2: Acid uptake comparison. % Acid uptake % Free salicylic acid % Theoretical coating level PVAP-based Acrylic-based PVAP-based with desiccant Acrylic-based with desiccant Figure 4: Free salicylic acid stability. PVAP-based Acrylic-based PVAP-based Acrylic-based Total coating time (h) Figure 3: Acid-resistance testing versus coating process time. tablets that were taken throughout the coating process were subjected to acid uptake testing as a measure of the necessary level of coating that would provide acceptable acid resistance. At 5% theoretical weight gain, the PVAP system exhibited less acid uptake than did the acrylic system, although both samples were well above the desired level of 5% acid uptake. Samples taken at weight gains of 6% and above all had acid uptake values of 4%. At 6% weight gain, the differences in acid uptake between the PVAP- and the acrylic-based systems did not exceed 0.63% (see Figure 2). Of concern in any coating process is the actual production time required to coat the tablets. As a batch operation, film coating is often a bottleneck in the manufacturing process. Long coating times are common for functional coatings because of the high amount of coating that must be applied as well as the need to ensure acid resistance. In the case of each enteric coating system tested in this study, the high solids concentrations and high spray rates enabled acceptable acid resistance in a relatively short time. The coating time needed to reach an acceptable level of acid resistance was 1.9 h for the acrylic-based system and 2.3 h for the PVAP-based system (see Figure 3). Dissolution testing confirmed that each system outperformed the USP requirements of 10% of ASA released in acid after 2 h and 80% released in ph 6.8 phosphate buffer within 90 min (see Table V). The USP limit for free salicylic acid in coated ASA tablets is 3.0%. It is critical to confirm that the humidity conditions and elevated temperatures in the coating process have not contributed to the degradation of the ASA. Samples taken from each trial at 6% and 10% (theoretical) weight gain had free salicylic acid levels of 0.16%. Coated-tablet stability. Dissolution and free salicylic acid content testing was conducted on the coated tablet samples after three months of storage at 40 C and 75% RH. The tablets were packaged both with and without desiccant packs as is seen in commercially available ASA products. The dissolution test results for the acrylic-coated tablet samples were virtually unchanged from the initial time point and passed USP delayedrelease requirements. The tablet samples coated with the PVAP-based system also passed the USP requirements except for the 6% weight gain sample with no desiccant in the package. The percent of ASA released in the acid phase was slightly higher overall with the PVAP system coated tablets but still well within the USP specification of 10% release (see Table VI). All tablet samples coated with either enteric coating system passed the requirements of 3% free salicylic acid. For the samples packaged without desiccant packages, the acrylic-based system had slightly higher free salicylic acid values. The addition of the desiccant packages resulted in lower free salicylic acid values (see Figure 4). Differences in the coating process conditions may explain the variation in free salicylic acid levels between the acrylic- and PVAPbased systems. Because acrylic-based systems coat at lower process temperatures, care must be taken to ensure that moisture is not absorbed by the tablet core during the coating process. Conclusion Optimum levels of enteric coating for the ASA 81-mg tablet were determined. Both fully formulated enteric coating systems, 42 Pharmaceutical Technology NOVEMBER

5 based on two different polymers, were comparable in overall process and acid resistance. Although traditional aqueous enteric coating systems can require multiple component mixing steps before coating, these systems were dispersed in one step in a minimum amount of time. Each system provided acceptable acid resistance to the ASA tablets at low weight gains and high application rates. The acrylic-based system offers the additional advantage of being fully pigmented, eliminating the need for an additional color application if a colored tablet is desired. Both systems also provided good stability in adverse storage conditions in this moisture-sensitive application. Acknowledgments The authors gratefully acknowledge James Taylor and Scott McBain of Colorcon for their help in the manufacture and coating of the ASA tablets. In addition, we thank David Ferrizzi, Laura Scattergood, and Buffy Young of Colorcon for their analytical support. Circle/eINFO 34 References 1. K. Lehmann, The Application and Processing of Acrylic Coatings in the Form of Aqueous Dispersions Compared with Organic Solutions, Acta Pharm. Fenn. 91, (1982). 2. C. Signorino, Aqueous Enteric Coating, Pharm. Technol. Tableting & Granulation Yearbook (1999). 3. N.A. Muhammad et al., Modifying the Release Properties of Eudragit L30D, Drug Dev. Ind. Pharm. 17 (18), (1991). 4. R. Bianchini, M. Resciniti, and C. Vecchio, Technological Evaluation of Aqueous Enteric Coating Systems with and without Insoluble Additives, Drug Dev. Ind. Pharm. 17 (13), (1991). 5. H. Erdmann et al., Suitability of Additives to Reduce the Tack of Kollicoat Coatings, in Proceedings of International Symposium of Controlled Release Bioactive Material (Controlled Release Society, Minneapolis, MN), 27 (2000). 6. C. Dangel et al., Aqueous Enteric Coatings with Methacrylic Acid Copolymer Type C on Basic and Acidic Drugs in Tablets and Pellets, Part 1: Acetylsalicylic Acid Tablets and Crystals, Pharm. Technol. 24 (3), (2000). 7. Acryl-Eze Preparation and Use Guidelines, technical information, Colorcon Limited, West Point, PA. 8. M.P. Jordan, J. Taylor, and P.J. Hadfield, A Comparison of the Performance Characteristics of Enteric Film Coating Systems, contributed paper presented at AAPS National Meeting, New Orleans, LA, October (1999). 9. Coating Aspirin with Sureteric in a 48-in. Accela-Cota, technical information, Colorcon, West Point, PA. 10. Acryl-Eze Coating Parameters, technical information, Colorcon, West Point, PA. PT Circle/eINFO Pharmaceutical Technology NOVEMBER

Formulation of Acetylsalicylic Acid Tablets for Aqueous Enteric Film Coating

Formulation of Acetylsalicylic Acid Tablets for Aqueous Enteric Film Coating Formulation of cetylsalicylic cid Tablets for queous Enteric Film Coating Charles R. Cunningham,* Bruce R. Kinsey, and Laura K. Scattergood COLORCON The goal of this study was to determine which combination

More information

Investigation of a New Coating Process for the Application of Enteric Coatings to Small Tablet Samples

Investigation of a New Coating Process for the Application of Enteric Coatings to Small Tablet Samples ACRYL-EZE Application Data Aqueous Acrylic Enteric System Investigation of a New Coating Process for the Application of Enteric Coatings to Small Tablet Samples INTRODUCTION The purpose of this study was

More information

Preparation of Robust, Enteric Coated Dosage Forms Utilizing Acryl-EZE and Aluminum Lake-Based Pigments

Preparation of Robust, Enteric Coated Dosage Forms Utilizing Acryl-EZE and Aluminum Lake-Based Pigments ACRYL-EZE Application Data Aqueous Acrylic Enteric System Preparation of Robust, Enteric Coated Dosage Forms Utilizing Acryl-EZE and Aluminum Lake-Based Pigments OBJECTIVES To prepare a one-step, aluminium

More information

Investigation of a Venlafaxine HCl (37.5 mg) Extended Release Formulation Using Hypromellose (HPMC) Matrices

Investigation of a Venlafaxine HCl (37.5 mg) Extended Release Formulation Using Hypromellose (HPMC) Matrices METHOCEL Application Data Partially Pregelatinized Maize Starch Investigation of a Venlafaxine HCl (37.5 mg) Extended Release Formulation Using Hypromellose (HPMC) Matrices ABSTRACT SUMMARY The aim of

More information

CHAPTER 8: SOLID DOSAGE FORM COATING TECHNOLOGY NOOR MUHAMMAD SYAHRIN BIN YAHYA INTRODUCTION

CHAPTER 8: SOLID DOSAGE FORM COATING TECHNOLOGY NOOR MUHAMMAD SYAHRIN BIN YAHYA INTRODUCTION CHAPTER 8: SOLID DOSAGE FORM COATING TECHNOLOGY NOOR MUHAMMAD SYAHRIN BIN YAHYA INTRODUCTION INTRODUCTION Coating technology is used extensively in the pharmaceutical industry, e.g. for the application

More information

Investigation of Aqueous Ethylcellulose Dispersion in Extended Release Metformin Inert Matrices

Investigation of Aqueous Ethylcellulose Dispersion in Extended Release Metformin Inert Matrices Surelease Application Data Aqueous Ethylcellulose Dispersion Investigation of Aqueous Ethylcellulose Dispersion in Extended Release Metformin Inert Matrices ABSTRACT SUMMARY: In the present study, Surelease,

More information

Table 1. Coating Process Conditions Used to Apply Enteric Coating. Parameter Trial 1 Trial 2 Trial 3. O'Hara LabCoat IIX (19" pan insert)

Table 1. Coating Process Conditions Used to Apply Enteric Coating. Parameter Trial 1 Trial 2 Trial 3. O'Hara LabCoat IIX (19 pan insert) PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-100 Page 1 of 6 Delayed-release Diclofenac Sodium Tablets: Scaling Up the Coating Process Bradley Beissner; Stuart C. Porter; Jeffrey

More information

Pharma Ingredients & Services. Kollicoat IR White. Technical Information

Pharma Ingredients & Services. Kollicoat IR White. Technical Information Technical Information Kollicoat IR White August 2008 Supersedes issue dated June 2008 EMP 040901e-10/Page 1 of 12 = Registered trademark of BASF SE Ready-to-use coating for instant-release dosage forms

More information

Methacrylic acid ethyl acrylate copolymer (1:1) dispersion 30 per cent (e.g. Kollicoat MAE 30 DP)

Methacrylic acid ethyl acrylate copolymer (1:1) dispersion 30 per cent (e.g. Kollicoat MAE 30 DP) Investigating the effect of partial neutralisation of the polymer on the dissolution characteristics of poly(methacrylic acid-co-ethyl acrylate) based coats Carolina Corell 1,3 ; Florian Bang 1 ; Thorsten

More information

* Current monograph name valid until May 1, 2017 ** New monograph name valid as of May 1, 2012, mandatory as of May 1, 2017

* Current monograph name valid until May 1, 2017 ** New monograph name valid as of May 1, 2012, mandatory as of May 1, 2017 Technical Information EUDRAGIT L 30 D-55 Specification and Test Methods Ph. Eur. Methacrylic Acid - Ethyl Acrylate Copolymer (1:1) Dispersion 30 Per Cent USP/NF Methacrylic Acid Copolymer Dispersion -

More information

Table 1. Particle size distributions and peroxide levels of various superdisintegrants. D50 (μm) D10 (μm)

Table 1. Particle size distributions and peroxide levels of various superdisintegrants. D50 (μm) D10 (μm) PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-97 Page 1 of 5 Utility of Polyplasdone crospovidone as a Superdisintegrant Quyen Schwing, Marvin Davis, Divya Tewari, Thomas Dürig

More information

The Use of Klucel Pharm Hydroxypropylcellulose to Increase the Utility of Hydroxypropyl Methylcellulose in Aqueous Film Coating

The Use of Klucel Pharm Hydroxypropylcellulose to Increase the Utility of Hydroxypropyl Methylcellulose in Aqueous Film Coating PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-049-1 (Supersedes PTR-049) Page 1 of 6 The Use of Klucel Pharm Hydroxypropylcellulose to Increase the Utility of Hydroxypropyl Methylcellulose

More information

PHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods

PHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-81 Page 1 of 5 Hot Melt Extrusion with Klucel hydroxypropylcellulose HPC for the Controlled Release of High Doses of a Highly Soluble

More information

Kollidon SR: A polyvinyl acetate based excipient for DCsustained-release

Kollidon SR: A polyvinyl acetate based excipient for DCsustained-release Kollidon SR: A polyvinyl acetate based excipient for DCsustained-release oral dosage forms by Dr. Bernhard Fussnegger BASF Aktiengesellschaft, Ludwigshafen Strategic Marketing Pharma Excipients Introduction

More information

(12) United States Patent

(12) United States Patent (12) United States Patent Jordan USOO6495163B1 (10) Patent No.: () Date of Patent: Dec. 17, 2002 (54) MOISTURE BARRIER FILM COATING COMPOSITION, METHOD AND COATED FORM (75) Inventor: Martin Philip Jordan,

More information

OPADRY II. Application Data

OPADRY II. Application Data OPADRY II Application Data High Performance Film Coating System Reducing Coated Tablet Defects from Laboratory through Production Scale: Performance of Hypromellose or Polyvinyl Alcohol-Based Aqueous Film

More information

Approval Application Form for Sakura Bloom Tablets

Approval Application Form for Sakura Bloom Tablets Approval Application Form for Sakura Bloom Tablets Mock-up for Columns of Manufacturing Methods and Specifications & Test Methods for Drug Products (sample description) Study project for regulatory harmonization

More information

INTRODUCTION TO INDUSTRIAL PHARMACY LAB 1

INTRODUCTION TO INDUSTRIAL PHARMACY LAB 1 INTRODUCTION TO INDUSTRIAL PHARMACY LAB 1 LAB INSTRUCTORS: LECT. ANAS T ARIK NAFEA ASSIST. LECT. ZAINAB HASSAN MAHDI Definition of Industrial Pharmacy The conversion of raw materials into certain dosage

More information

coating Layering an API onto tablets using a perforated-drum coater: A case study ACG Pharma Technologies

coating Layering an API onto tablets using a perforated-drum coater: A case study ACG Pharma Technologies As appeared in Tablets & Capsules April 201 coating www.tabletscapsules.com Layering an API onto tablets using a perforated-drum coater: A case study Vasant Shetty, Sameer Borate, Anuprita Landge, and

More information

PHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods

PHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-079 Page 1 of 5 Advantages of Hot Melt Extrusion for the Controlled Release of High Doses of Highly Soluble Actives E. Pinto, H. Yang,

More information

Pharma Ingredients & Services. Ludiflash. Technical Information

Pharma Ingredients & Services. Ludiflash. Technical Information Technical Information Ludiflash March 2012 Supersedes issue dated August 2011 03_070805e-03/Page 1 of 10 = Registered trademark of BASF group Excipient for fast-disintegrating oral dosage forms Direct

More information

Soluplus. Technical Information. October _090801e-01/Page 1 of 8. = Registered trademark of BASF group. Pharma Ingredients & Services

Soluplus. Technical Information. October _090801e-01/Page 1 of 8. = Registered trademark of BASF group. Pharma Ingredients & Services Technical Information Soluplus October 2009 03_090801e-01/Page 1 of 8 = Registered trademark of BASF group Pharma Ingredients & Services 03_090801e-01 October 2009 Page 2 of 8 Soluplus 1. Introduction

More information

Table Formula of Levodopa + Benserazide HCl capsule (batch no. 004 to 008)

Table Formula of Levodopa + Benserazide HCl capsule (batch no. 004 to 008) Introduction After using pearlitol SD (200) along with avicel ph 112 the flow of the blend was improved but still not up to the mark. Weight variation was observed around (11.47%) which was not acceptable.

More information

Table 1: Coating Compositions. Layer Ingredient g Drug-binder solution

Table 1: Coating Compositions. Layer Ingredient g Drug-binder solution Poster Reprint Controlled Release Society July 7 Application of an Aqueous Ethylcellulose Dispersion in Multiple-Unit Pellet Systems. Viena D. Dias, Kurt Fegely, Abhijit V. Gothoskar and Ali R. Rajabi-Siahboomi

More information

New Developments in Spray-Dried Lactose

New Developments in Spray-Dried Lactose New Developments in Spray-Dried Lactose Gerad Bolhuis, Klaas Kussendrager, and John Langridge* Recent advances in spraydrying technology have led to the production of new directly compressible lactose

More information

Hydroxypropylcellulose Polymer Molecular Weight: Influence on Erodible Modified Release Matrix Systems By T. Dürig, W.W. Harcum, and R. A.

Hydroxypropylcellulose Polymer Molecular Weight: Influence on Erodible Modified Release Matrix Systems By T. Dürig, W.W. Harcum, and R. A. PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-032-1 (Supersedes PTR-032) Page 1 of 7 Hydroxypropylcellulose Polymer Molecular Weight: Influence on Erodible Modified Release Matrix

More information

Effect of Formulation and Process Variables

Effect of Formulation and Process Variables Effect of Formulation and Process Variables On Matrix Erosion and Drug Release from a Multiunit Erosion Matrix of a Poorly Soluble Drug Ketan A. Mehta, M. Serpil Kislalioglu,* Wantanee Phuapradit, A. Waseem

More information

FILM COATINGS. Process Adaptability for the Perfect Finish. Productivity Enhancement and Efficiency Wide Processing Latitude Excellent Appearance

FILM COATINGS. Process Adaptability for the Perfect Finish. Productivity Enhancement and Efficiency Wide Processing Latitude Excellent Appearance FILM COATINGS Process Adaptability for the Perfect Finish Productivity Enhancement and Efficiency Wide Processing Latitude Excellent Appearance Process Adaptability for the Perfect Finish Opadry QX, quick

More information

Pharma Ingredients & Services. Ludiflash. Technical Information

Pharma Ingredients & Services. Ludiflash. Technical Information Technical Information Ludiflash April 2008 Supersedes issue dated September 2007 EMP 070805e-01/Page 1 of 12 = Registered trademark of BASF SE Excipient for fast-disintegrating oral dosage forms Direct

More information

Effects of Core Tablet Size on the Functionality of Aqueous Delayed Release Coatings as Measured by SEM and LIBS

Effects of Core Tablet Size on the Functionality of Aqueous Delayed Release Coatings as Measured by SEM and LIBS Acryl-EZE MP Poster Reprint Aqueous Acrylic Enteric System Effects of Core Tablet Size on the Functionality of Aqueous Delayed Release Coatings as Measured by SEM and LIBS PURPOSES The aim of this work

More information

PHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Methods. Ashland Specialty Ingredients ashland.com

PHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Methods. Ashland Specialty Ingredients ashland.com PHARMACEUTICAL TECHNOLOGY REPORT Ashland Specialty ashland.com PTR-96 Page 1 of 5 Utility of Polyplasdone crospovidone as a Solubilizer Quyen Schwing, Marvin Davis, Divya Tewari, Thomas Dürig Ashland Specialty,

More information

f a c t s T C C T B Tricalcium citrate as excipient for direct compression

f a c t s T C C T B Tricalcium citrate as excipient for direct compression f a c t s T C C T B Tricalcium citrate as excipient for direct compression Direct compression has gained enormous popularity in tablet manufacturing in recent times. It is seen as the most economic process

More information

Amount of individual ingredients added (g) Surelease dispersion*

Amount of individual ingredients added (g) Surelease dispersion* Poster Reprint AAPS Annual Meeting November 27 The Influence of Hydrophilic Pore Formers on Dipyridamole Release from Aqueous Ethylcellulose Film-Coated Pellets Dasha Palmer, Hue Vuong, Marina Levina and

More information

THE PROCESS VALIDATION OF TABLET CONTAINING IRBESARTAN 300MG AND HYDROCHLOROTHIAZIDE 12.5mg Zamir Hussain, Baqir Shyum Naqvi & Muhammad Iqbal Nasiri

THE PROCESS VALIDATION OF TABLET CONTAINING IRBESARTAN 300MG AND HYDROCHLOROTHIAZIDE 12.5mg Zamir Hussain, Baqir Shyum Naqvi & Muhammad Iqbal Nasiri THE PROCESS VALIDATION OF TABLET CONTAINING IRBESARTAN 300MG AND HYDROCHLOROTHIAZIDE 12.5mg Zamir Hussain, Baqir Shyum Naqvi & Muhammad Iqbal Nasiri Faculty of Pharmacy, Department of Pharmaceutics, Hamdard

More information

TASTE MASKING WITH COATINGS. Coating Technology 96 October 8-9, Presented by Ralph E. Pondell Corporate Secretary

TASTE MASKING WITH COATINGS. Coating Technology 96 October 8-9, Presented by Ralph E. Pondell Corporate Secretary 96-2 TASTE MASKING WITH COATINGS Coating Technology 96 October 8-9, 1996 Presented by Ralph E. Pondell Corporate Secretary Coating Place, Inc. P.O. Box 930310 Verona, WI 53593 (608) 845-9521 When dealing

More information

Film Coating Process Considerations for the Application of High Productivity, High Solids Concentration Film Coating Formulations

Film Coating Process Considerations for the Application of High Productivity, High Solids Concentration Film Coating Formulations Opadry II Application Data High Productivity Film Coating System Film Coating Process Considerations for the Application of High Productivity, High Solids Concentration Film Coating Formulations PURPOSE

More information

Real-Time Prediction of Polymer-Coated Multiparticulate Dissolution using Process Analytical Technology

Real-Time Prediction of Polymer-Coated Multiparticulate Dissolution using Process Analytical Technology Real-Time Prediction of Polymer-Coated Multiparticulate Dissolution using Process Analytical Technology Authors: Piyush Patel A, Edward Godek B, Chris O Callaghan C, Dr. Ian Jones D A Colorcon, PA, USA

More information

MEETING YOUR CHALLENGES TODAY AND TOMORROW. Avicel PH BINDERS

MEETING YOUR CHALLENGES TODAY AND TOMORROW. Avicel PH BINDERS MEETING YOUR CHALLENGES TODAY AND TOMORROW Avicel PH BINDERS FORMULA Functionality and Consistency... 02 Applications... 03 Direct compression... 03 Wet granulation... 04 Dry granulation... 04 Hard capsules...

More information

NISSO HPC for Pharmaceutical Applications

NISSO HPC for Pharmaceutical Applications NISSO HPC for Pharmaceutical Applications Contents Introduction Features of NISSO HPC Major Application of NISSO HPC NISSO HPC Grades and Availability How to use based on Application and Features of NISSO

More information

Dow Pharma Solutions. ETHOCEL High Productivity (HP) Polymers Safe. Fast. Efficient.

Dow Pharma Solutions. ETHOCEL High Productivity (HP) Polymers Safe. Fast. Efficient. Dow Pharma Solutions ETHOCEL High Productivity (HP) Polymers Safe. Fast. Efficient. Improving Productivity Through Innovation ETHOCEL Polymers is the oldest trademarked brand available from The Dow Chemical

More information

One non-numeric process related variable examined was post coating thermal (curing) treatment.

One non-numeric process related variable examined was post coating thermal (curing) treatment. Poster Reprint AAPS Annual Meeting November 27 Identification and Influence of Critical Coating Process Parameters on Drug Release from a Fully Formulated Aqueous Ethylcellulose Dispersion Charles F. Vesey,

More information

Behavior of Uptake of Moisture by Drugs and Excipients under

Behavior of Uptake of Moisture by Drugs and Excipients under Behavior of Uptake of Moisture by Drugs and Excipients under Accelerated Conditions of Temperature and Humidity in the Absence and the Presence of Light Part II: Packaged and Unpackaged Antituberculosis

More information

Malukani et al., IJPSR, 2012; Vol. 3(7): ISSN:

Malukani et al., IJPSR, 2012; Vol. 3(7): ISSN: IJPSR (2012), Vol. 3, Issue 07 (Research Article) Received on 27 March, 2012; received in revised form 17 June, 2012; accepted 25 June, 2012 PROCESS VALIDATION OF SOTALOL HYDROCHLORIDE TABLETS J.N. Malukani*

More information

ETHOCEL High Productivity (HP) Polymers Safe. Fast. Efficient.

ETHOCEL High Productivity (HP) Polymers Safe. Fast. Efficient. Dow Pharma Solutions ETHOCEL High Productivity (HP) Polymers Safe. Fast. Efficient. This document is valid at the time of distribution. Distributed 22-?-218 (UTC) Improving Productivity Through Innovation

More information

Extended-release Venlafaxine Pellets: Scaling Up the Coating Process Stuart C. Porter, Bradley Beissner and Jeffrey Williamson

Extended-release Venlafaxine Pellets: Scaling Up the Coating Process Stuart C. Porter, Bradley Beissner and Jeffrey Williamson PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-104 Page 1 of 6 Extended-release Venlafaxine Pellets: Scaling Up the Coating Process Stuart C. Porter, Bradley Beissner and Jeffrey

More information

ETHOCEL High Productivity (HP) Polymers Safe. Fast. Efficient.

ETHOCEL High Productivity (HP) Polymers Safe. Fast. Efficient. Dow Pharma Solutions ETHOCEL High Productivity (HP) Polymers Safe. Fast. Efficient. This document is valid at the time of distribution. Distributed 7-Oct-218 (UTC) Improving Productivity Through Innovation

More information

Seamless Integration of a Semi- Continuous Coating Process into Existing Solid Dosage Production

Seamless Integration of a Semi- Continuous Coating Process into Existing Solid Dosage Production Seamless Integration of a Semi- Continuous Coating Process into Existing Solid Dosage Production Abstract A study was conducted using the KOCO 25 in conjunction with the ROB 50, in order to provide insight

More information

The Role of Polymer Excipients in Hot Melt Extrusion A Continuous Manufacturing Process

The Role of Polymer Excipients in Hot Melt Extrusion A Continuous Manufacturing Process The Role of Polymer Excipients in Hot Melt Extrusion A Continuous Manufacturing Process Nigel Langley ExcipientFest May 1, 2018 Hot-Melt Extrusion A Continuous Manufacturing Process Principle of HME 2

More information

Dissolution Enhancement of Haloperidol Tablets using ph Modifier and Co-Solubilizer

Dissolution Enhancement of Haloperidol Tablets using ph Modifier and Co-Solubilizer Human Journals Research Article June 2015 Vol.:3, Issue:3 All rights are reserved by Ruby Ujawane et al. Dissolution Enhancement of Haloperidol Tablets using ph Modifier and Co-Solubilizer Keywords: Haloperidol,

More information

TABLET COATING. Lec. 8

TABLET COATING. Lec. 8 TABLET COATING Lec. 8 TABLET COATING PRINCIPLES History: Tab. coating starts with Rhazes (coated food) in 800s then developed by Frenches (sugar coat) in 1800s and finally Abbott marketed (film coat) in

More information

Tricalcium citrate as excipient for direct compression

Tricalcium citrate as excipient for direct compression f a c t s T C C T B Tricalcium citrate as excipient for direct compression Introduction Direct compression has gained enormous popularity in tablet manufacturing in recent times. It is seen as the most

More information

Kollicoat IR. The application of Kollicoat IR as a Zero Peroxide Binder for use in Solid Oral Dosage Forms. ExcipientFest.

Kollicoat IR. The application of Kollicoat IR as a Zero Peroxide Binder for use in Solid Oral Dosage Forms. ExcipientFest. Kollicoat IR The application of Kollicoat IR as a Zero Peroxide Binder for use in Solid Oral Dosage Forms ExcipientFest Nigel Langley Market Need Platforms Instant & Modified Release Solubilization Skin

More information

Maximizing Roller Compaction Benefits with Proper Excipient Selection

Maximizing Roller Compaction Benefits with Proper Excipient Selection A sponsored whitepaper. Maximizing Roller Compaction Benefits with Proper Excipient Selection By: Bernhard Fussnegger, Global Development and Technical Marketing, PVP/Coatings, Instant & Modified Release,

More information

Pharma Ingredients & Services. Kollidon VA 64 Kollidon VA 64 Fine. Copovidone Ph.Eur., USP, Copolyvidone JPE. Technical Information

Pharma Ingredients & Services. Kollidon VA 64 Kollidon VA 64 Fine. Copovidone Ph.Eur., USP, Copolyvidone JPE. Technical Information Technical Information June 2008 Supersedes issue dated October 2007 EMP 050602e-05/Page 1 of 16 Kollidon VA 64 Kollidon VA 64 Fine Copovidone Ph.Eur., USP, Copolyvidone JPE = Registered trademark of BASF

More information

How to Identify Critical Quality Attributes and Critical Process Parameters

How to Identify Critical Quality Attributes and Critical Process Parameters How to Identify Critical Quality Attributes and Critical Process Parameters Jennifer Maguire, Ph.D. Daniel Peng, Ph.D. Office of Process and Facility (OPF) OPQ/CDER/FDA FDA/PQRI 2 nd Conference North Bethesda,

More information

Preparation and Evaluation of Sustained Release Tablet of Cyproheptadine Hydrochloride Using Carbopol and HPMC

Preparation and Evaluation of Sustained Release Tablet of Cyproheptadine Hydrochloride Using Carbopol and HPMC Received: 06-01-2013 Accepted: 26-02-2013 ISSN: 2277-7695 CODEN Code: PIHNBQ ZDB-Number: 2663038-2 IC Journal No: 7725 Vol. 2 No. 1 2013 Online Available at www.thepharmajournal.com THE PHARMA INNOVATION

More information

EVALUATION OF NEW FILM COATING PROCESSES AND MATERIALS

EVALUATION OF NEW FILM COATING PROCESSES AND MATERIALS EVALUATION OF NEW FILM COATING PROCESSES AND MATERIALS Inaugural-Dissertation zur Erlangung der Doktorwurde im Fachbereich Biologie, Chemie, Pharmazie der Freien Universitat Berlin vorgelegt von NANTHARAT

More information

Kollidon VA 64. Technical Information. Copovidone Ph.Eur.

Kollidon VA 64. Technical Information. Copovidone Ph.Eur. Technical Information ME 080 e (939) March 2000 (MPM) Kollidon VA 64 Copovidone Ph.Eur. Register 2 = Registered trademark of BASF Aktiengesellschaft Kollidon VA 64 is a vinylpyrrolidone-vinyl acetate copolymer

More information

Dissolution Enhancement of Active Pharmaceutical Ingredients in Eudragit E100 by Melt Extrusion Coupled with Supercritical Carbon Dioxide

Dissolution Enhancement of Active Pharmaceutical Ingredients in Eudragit E100 by Melt Extrusion Coupled with Supercritical Carbon Dioxide Dissolution Enhancement of Active Pharmaceutical Ingredients in Eudragit E100 by Melt Extrusion Coupled with Supercritical Carbon Dioxide Martial SAUCEAU 1, Tamás VIGH 2, Elisabeth RODIER 1, Zsombor NAGY

More information

Pharma Ingredients & Services. Soluplus. Technical Information. = Registered trademark of BASF group. July 2010 Supersedes issue dated May 2010

Pharma Ingredients & Services. Soluplus. Technical Information. = Registered trademark of BASF group. July 2010 Supersedes issue dated May 2010 Technical Information Soluplus July 21 Supersedes issue dated May 21 3_981e-4/Page 1 of 8 = Registered trademark of BASF group Pharma Ingredients & Services 3_981e-4 July 21 Page 2 of 8 Soluplus 1. Introduction

More information

International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:

International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage: Review Article CODEN: IJRPJK ISSN: 2319 9563 International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage: www.ijrpns.com REVIEW ARTICLE ON INPROCESS PROBLEMS AND EVALUATION TESTS

More information

Design of Controlled Release Non-erodible Polymeric Matrix Tablet Using Microwave Oven-assisted Sintering Technique

Design of Controlled Release Non-erodible Polymeric Matrix Tablet Using Microwave Oven-assisted Sintering Technique Pharmaceutics Design of Controlled Release Non-erodible Polymeric Matrix Tablet Using Microwave Oven-assisted Sintering Technique Patel DM Patel BK Patel A Patel CN Department of Pharmaceutics and Pharmaceutical

More information

AN INTRODUCTION TO SPHERONIZATION (MARUMERIZATION * )

AN INTRODUCTION TO SPHERONIZATION (MARUMERIZATION * ) A TECHNICAL NOTE LABORATORY / PRODUCTION CALEVA (MARUMERIZATION * ) A Brief Non-Technical General Guide interchangeably. *Spheronization and marumerization, different names for the same thing. The two

More information

Excipient Development at NCL

Excipient Development at NCL New Reverse Enteric Polymer for Oral Dosage Forms Excipient Development at omplete Solution for Taste Masking Moisture Barrier Sustained Release Immediate Release Polymorphism Inhibition National hemical

More information

ANNEX V ASEAN GUIDELINES ON STABILITY STUDY AND SHELF-LIFE OF HEALTH SUPPLEMENTS

ANNEX V ASEAN GUIDELINES ON STABILITY STUDY AND SHELF-LIFE OF HEALTH SUPPLEMENTS Association of South East Asian Nations (ASEAN) ANNEX V ASEAN GUIDELINES ON STABILITY STUDY AND SHELF-LIFE OF HEALTH SUPPLEMENTS Disclaimer: This document is provided for information purpose only and subject

More information

Stability Report. Stability profile of. BIWG 98 SE tablets 40 mg SR of 133. This stability report comprises 133 pages.

Stability Report. Stability profile of. BIWG 98 SE tablets 40 mg SR of 133. This stability report comprises 133 pages. Stability Report Stability profile of BIWG 98 SE tablets 40 mg Number SR 2001-01-04-01 Date Page 00. 00. 0000 1 of 133 Responsible Company Successful Pharma KG Biberach This stability report comprises

More information

PHARMACEUTICAL TECHNOLOGY REPORT. Introduction

PHARMACEUTICAL TECHNOLOGY REPORT. Introduction PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-036-1 (Supersedes PTR-036) Page 1 of 9 Water-Soluble Cellulose Ethers as Release Modulators for Ethylcellulose Coatings on Multiparticulates

More information

7th Training School on Microencapsulation Strasbourg. Februar 2015 Textmasterformat in Mastervorlage eingeben

7th Training School on Microencapsulation Strasbourg. Februar 2015 Textmasterformat in Mastervorlage eingeben 7th Training School on Microencapsulation Strasbourg Februar 2015 1 Dr. Anne Ettner, Glatt Pharmaceutical Services 2 Overview 1. Introduction 2. Fluid bed equipment 3. Basics of fluid bed Wurster technology

More information

Prediction of suitable amounts of water in fluidized bed granulation of pharmaceutical formulations using corresponding values of components

Prediction of suitable amounts of water in fluidized bed granulation of pharmaceutical formulations using corresponding values of components Available online at www.sciencedirect.com International Journal of Pharmaceutics 352 (2008) 202 208 Prediction of suitable amounts of water in fluidized bed granulation of pharmaceutical formulations using

More information

University of Sulaimani College of Pharmacy Dept. of Pharmaceutics 5 th stage Second Semester

University of Sulaimani College of Pharmacy Dept. of Pharmaceutics 5 th stage Second Semester University of Sulaimani College of Pharmacy Dept. of Pharmaceutics 5 th stage Second Semester 2/26/2018 Industrial Pharmacy II, Dr. rer. nat. Rebaz Ali 1 Outlines Powder flow Introduction Factor affecting

More information

ADVANTAGES OF MULTIPARTICULATES (PELLETS):

ADVANTAGES OF MULTIPARTICULATES (PELLETS): INTRODUCTION: Multiparticulate Drug Delivery Systems (MDDS): The concept of multiple unit dosage form was initially introduced in the early 1950 s.these forms play a major role in the design of solid dosage

More information

BY ARJUN NARALA M.PHARMACY, I SEM DEPARTMENT OF PHARMACEUTICS UNIVERSITY COLLEGE OF PHARMACEUTICAL SCIENCES KAKATIYA UNIVERSITY WARANGAL.

BY ARJUN NARALA M.PHARMACY, I SEM DEPARTMENT OF PHARMACEUTICS UNIVERSITY COLLEGE OF PHARMACEUTICAL SCIENCES KAKATIYA UNIVERSITY WARANGAL. BY ARJUN NARALA M.PHARMACY, I SEM DEPARTMENT OF PHARMACEUTICS UNIVERSITY COLLEGE OF PHARMACEUTICAL SCIENCES KAKATIYA UNIVERSITY WARANGAL. CONTENTS Introduction Defects in Tablets Defects in sugar coated

More information

In the normal process of developing formulations, and in the routine manufacture of tablets, various defects are observed. Sometimes, the source of

In the normal process of developing formulations, and in the routine manufacture of tablets, various defects are observed. Sometimes, the source of In the normal process of developing formulations, and in the routine manufacture of tablets, various defects are observed. Sometimes, the source of the problem or the defect is the formulation, the compression

More information

Formulation and Evaluation of Telmisartan with Hydrochlorothiazide Conventional Release Tablets

Formulation and Evaluation of Telmisartan with Hydrochlorothiazide Conventional Release Tablets Human Journals Research Article July 2018 Vol.:12, Issue:4 All rights are reserved by S. Meena et al. Formulation and Evaluation of Telmisartan with Hydrochlorothiazide Conventional Release Tablets Keywords:

More information

Scuffing Measurement Methodology and Improved Film Coating Systems

Scuffing Measurement Methodology and Improved Film Coating Systems OPADRY II Application Data High Performance Film Coating System Scuffing Measurement Methodology and Improved Film Coating Systems PURPOSE Scuffing is a term used to describe coated tablet defects consisting

More information

Elvacite 2823 Acrylic Resin for low VOC

Elvacite 2823 Acrylic Resin for low VOC Elvacite 2823 Acrylic Resin for low VOC Acrylic Resin Elvacite 2823 is a methyl methacrylate copolymer designed for use in VOC compliant coatings. Elvacite 2823 utilizes patented technology to provide

More information

Validation of the Cleaning In Place of the coating pan PERFIMA, IMA

Validation of the Cleaning In Place of the coating pan PERFIMA, IMA Validation of the Cleaning In Place of the coating pan PERFIMA, IMA Author Prof. Ruggero Bettini Published in October 26 Università degli Studi di Parma, Dipartimento Farmaceutico Viale G. P. Usberti,

More information

Process Validation of Oral Solid Dosage Form-Tablet containing Anti Tubercular Agent

Process Validation of Oral Solid Dosage Form-Tablet containing Anti Tubercular Agent Available online on www.ijpqa.com International Journal of Pharmaceutical Quality Assurance; 4(3); 27-36 Research Article ISSN 05 06 Process Validation of Oral Solid Dosage Form-Tablet containing Anti

More information

SUSTAINED RELEASE From Coated Ion Exchange Resins. H.S. Hall Coating Place, Inc. Verona, WI 53593

SUSTAINED RELEASE From Coated Ion Exchange Resins. H.S. Hall Coating Place, Inc. Verona, WI 53593 SUSTAINED RELEASE From Coated Ion Exchange Resins 79-1 by H.S. Hall Coating Place, Inc. Verona, WI 53593 A substantial amount of work has been published concerning the use of ion exchange resins for sustained

More information

Streamlined Manufacture of Modified Release Matrix Tablets via Direct Compression. Katie Hewlett, Dow Gus LaBella, Colorcon

Streamlined Manufacture of Modified Release Matrix Tablets via Direct Compression. Katie Hewlett, Dow Gus LaBella, Colorcon Streamlined Manufacture of Modified Release Matrix Tablets via Direct Compression Katie Hewlett, Dow Gus LaBella, Colorcon Controlled Release Alliance Unique Together Leading polymer expertise Quality

More information

THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION

THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION Pharmacopeial Forum Vol. 31(5)(Sept.-Oct. 2005) By : Mr. Seubpong Kumpusiri Mrs. Patima Maneesatid 26 May 2006 THE DISSOLUTION PROCEDURE: DEVELOPMENT

More information

DRY COATING : Techniques & Potentials

DRY COATING : Techniques & Potentials Water in Food Workshop Lausanne 2004 DRY COATING : Techniques & Potentials E. TEUNOU - E. IVANOVA - D. PONCELET Nantes Département du Génie des Procédés Alimentaire Content Who are we? Importance and Functionality

More information

QbD implementation in Generic Industry: Overview and Case-Study

QbD implementation in Generic Industry: Overview and Case-Study QbD implementation in Generic Industry: Overview and Case-Study Inna Ben-Anat, QbD Strategy Leader, Teva Pharmaceuticals IFPAC JAN 2013 R&D Three Core Components of QbD and Generic Industry: How Do They

More information

International Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: Vol.7, No.1, pp ,

International Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: Vol.7, No.1, pp , International Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: 0974-4304 Vol.7, No.1, pp 139-147, 2014-2015 Pharmaceutical Prospective Process Validation Of Chloroquiune Tablets Vilas S Jadhav*,

More information

Copyright CSC Publishing

Copyright CSC Publishing As appeared in March 2014 roller compaction www.tabletscapsules.com Effect of roller compaction pressure on the blend and tablet properties of a formulation containing a poorly soluble drug E. E. Robles,

More information

WHOPAR. SCIENTIFIC DISCUSSION

WHOPAR. SCIENTIFIC DISCUSSION This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1

More information

Formulation Development & CTM Manufacturing Services

Formulation Development & CTM Manufacturing Services Formulation Development & CTM Manufacturing Services VxP Pharma Purdue Research Park 5225 Exploration Drive Indianapolis, IN 46241 Tel: 317.759.2299 Fax: 317.713.2950 VxP Pharmaprovides an extensive range

More information

HARD TWO-PIECE HPMC CAPSULES FOR PHARMACEUTICAL APPLICATIONS

HARD TWO-PIECE HPMC CAPSULES FOR PHARMACEUTICAL APPLICATIONS HARD TWO-PIECE HPMC CAPSULES FOR PHARMACEUTICAL APPLICATIONS QUALICAPS HISTORY Over one hundred years of experience in the manufacturing and filling of hard two-piece capsules Qualicaps originated within

More information

Direct Compression Microcrystalline Cellulose Grade 12 versus Classic Grade 102

Direct Compression Microcrystalline Cellulose Grade 12 versus Classic Grade 102 Direct Compression Microcrystalline Cellulose Grade 1 versus Classic Grade 1 Masaki Hasegawa The author compared the behavior of two grades of microcrystalline cellulose during the direct-compression process.

More information

Ahmed et al., Received- 5 February 2009 Accepted for Publication- 1 March, 2009

Ahmed et al., Received- 5 February 2009 Accepted for Publication- 1 March, 2009 The Effect of Manufacturing Methods and Different Shapes on the Release Pattern of Diclofenac Sodium Matrix Tablet Tajnin Ahmed 1, Muhammad Shahidul Islam 2*, Tasnuva Haque 1, Mohammad Abusyed 3 1 Department

More information

Preparation of Antipyretic Analgesic by Direct Compression and Its Evaluation

Preparation of Antipyretic Analgesic by Direct Compression and Its Evaluation 1542 Chem. Pharm. Bull. 50(12) 1542 1549 (2002) Vol. 50, No. 12 Preparation of Antipyretic Analgesic by Direct Compression and Its Evaluation Keijiro TERASHITA* and Keisuke IMAMURA Osaka Prefecture University,

More information

PHARMACEUTICAL PRINCIPLES OF SOLID DOSAGE FORMS

PHARMACEUTICAL PRINCIPLES OF SOLID DOSAGE FORMS PHARMACEUTICAL PRINCIPLES OF SOLID DOSAGE FORMS J. T. Carstensen, Ph.D. Professor of Pharmacy University of Wisconsin Madison, Wisconsin TECHNOMIC ^PUBLISHING CO.. INC J 1.ANCASTER BASET, TABLE OF CONTENTS

More information

METHOCEL. TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow

METHOCEL. TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow METHOCEL Cellulose Ethers A product that can do it all TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow The possibilities are endless Pharmaceutical companies are continuously

More information

Comparative analysis of eight brands of sulfadoxinepyrimethamine

Comparative analysis of eight brands of sulfadoxinepyrimethamine Tropical Journal of Pharmaceutical Research, June 2003; 2 (1): 161-167 Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria. All rights reserved. Available online at http://www.tjpr.freehosting.net

More information

Asian Journal of Research in Pharmaceutical Sciences and Biotechnology

Asian Journal of Research in Pharmaceutical Sciences and Biotechnology Research Article ISSN: 2349 7114 Asian Journal of Research in Pharmaceutical Sciences and Biotechnology Journal home page: www.ajrpsb.com FORMULATION DEVELOPMENT AND EVALUATION OF PANTOPRAZOLE DELAYED

More information

International Journal of Pharmacy

International Journal of Pharmacy International Journal of Pharmacy Journal Homepage: http://www.pharmascholars.com Research Article CODEN: IJPNL6 FORMULATION AND EVALUATION OF SUSTAINED RELEASE MATRIX TABLETS OF RANOLAZINE M Vanaja kumari

More information

THE PHYSICAL CHARACTERISTICS OF LYOPHILIZED TABLETS CONTAINING A MODEL DRUG IN DIFFERENT CHEMICAL FORMS AND CONCENTRATIONS

THE PHYSICAL CHARACTERISTICS OF LYOPHILIZED TABLETS CONTAINING A MODEL DRUG IN DIFFERENT CHEMICAL FORMS AND CONCENTRATIONS Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 62 No. 1 pp. 25ñ29, 2005 ISSN 0001-6837 Polish Pharmaceutical Society DRUG TECHNOLOGY THE PHYSICAL CHARACTERISTICS OF LYOPHILIZED TABLETS CONTAINING A

More information

4.4 MICROBIOLOGICAL METHOD FOR THE ESTIMATION OF. The microbiological assay was performed by using the test

4.4 MICROBIOLOGICAL METHOD FOR THE ESTIMATION OF. The microbiological assay was performed by using the test 109 4.4 MICROBIOLOGICAL METHOD FOR THE ESTIMATION OF AMOXICILLIN The microbiological assay was performed by using the test organism Staphylococcus aureus. The strain was isolated from soil and allowed

More information

Sakura Bloom Tablets P2 Mock

Sakura Bloom Tablets P2 Mock Sakura Bloom Tablets P2 Mock Mock P2 English version Sakura Bloom Tablets Disclaimer This mock provides an example of the contents to be included in CTD 2.3.P.2 Pharmaceutical Development section for a

More information

International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:

International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage: Research Article CODEN: IJRPJK ISSN: 2319 9563 International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage: www.ijrpns.com FORMULATION AND EVALUATION OF ESOMEPRAZOLE MAGNESIUM

More information